Nuclear Medicine and Molecular Imaging

  • 제43권2호
  • /
  • Pages.120-128
  • /
  • 2009
  • /
  • 1869-3474(pISSN)
  • /
  • 1869-3482(eISSN)
대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

대장암 치료 후 추적 검사로서 F-18 FDG PET/CT의 역할: 혈청 CEA, CA 19-9 및 Computed Tomography와의 진단 성능 비교

Diagnostic Role of F-18 FDG PET/CT in the Follow-up of Patients with Colorectal Cancer: Comparison with Serum CEA, CA 19-9 Levels and Computed Tomography

  • 강성민 (경북대학교 의과대학 핵의학교실) ;
  • 송봉일 (경북대학교 의과대학 핵의학교실) ;
  • 이홍제 (경북대학교 의과대학 핵의학교실) ;
  • 서지형 (경북대학교 의과대학 핵의학교실) ;
  • 이상우 (경북대학교 의과대학 핵의학교실) ;
  • 유정수 (경북대학교 의과대학 핵의학교실) ;
  • 안병철 (경북대학교 의과대학 핵의학교실) ;
  • 이재태 (경북대학교 의과대학 핵의학교실) ;
  • 최규석 (경북대학교 의과대학 외과학교실) ;
  • 전수한 (경북대학교 의과대학 외과학교실)
  • Kang, Sung-Min (Department of Nuclear Medicine, Kyungpook National University Hospital) ;
  • Song, Bong-Il (Department of Nuclear Medicine, Kyungpook National University Hospital) ;
  • Lee, Hong-Je (Department of Nuclear Medicine, Kyungpook National University Hospital) ;
  • Seo, Ji-Hyoung (Department of Nuclear Medicine, Kyungpook National University Hospital) ;
  • Lee, Sang-Woo (Department of Nuclear Medicine, Kyungpook National University Hospital) ;
  • Yoo, Jeong-Soo (Department of Nuclear Medicine, Kyungpook National University Hospital) ;
  • Ahn, Byeong-Cheol (Department of Nuclear Medicine, Kyungpook National University Hospital) ;
  • Lee, Jae-Tae (Department of Nuclear Medicine, Kyungpook National University Hospital) ;
  • Choi, Kyu-Suk (Department of Surgery, Kyungpook National University Hospital) ;
  • Jun, Soo-Han (Department of Surgery, Kyungpook National University Hospital)
  • 발행 : 2009.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 대장암 재발의 조기진단은 생존율을 증가시키는 중요한 인자이다. 대장암의 재발이나 전이를 진단하는데 있어 혈청 CEA, CA 19-9 등의 종양표지 자와 CT 등의 가장 많이 이용되어 왔고 최근 새로운 진단기술로서 PET/CT의 이용이 증가되고 있다. 이 연구에서는 근치적 수술을 포함한 치료를 시행하고 재발이나 전이의 증거가 없었던 상태에서 추적관찰을 받았던 대장암 환자에서 FDG PET/CT의 정기 추적 검사로서의 진단 성능을 혈청 CEA, CA 19-9, CT와 비교하고자 시행하였다 대상 및 방법: 수술적 치료 후 추적관찰 중인 대장암 환자 189명을 대상으로 하였다. PET/CT상에서 관찰된 비정상적인 FDG 섭취 증가 병소는 생검이나 6개월 이상 방사선학적 검사의 추적관찰로서 전이여부 판단하였다. PET/CT시행시기에서 6주 이내에 모든 환자에서 혈청 CEA, 174명의 환자에서 CA 19-9를 측정하였다. 115명의 환자에서 PET/CT 시행 시기 2개월 이내에 CT를 시행하였다. PET/CT 상에서 관찰된 비정상적인 FDG 셥취 증가 병소는 생검이나 6개월 이내의 방사선학적 검사와 임상적 진단의 추적 관찰로 재발이나 전이 병소로 진단하였다. 결과: 국소적 재발 및 전이가 발견된 환자는 76명(40.2%)이었다. 재발 또는 전이 병소는 총 81개였고 간과 폐에서 29개와 16개로 가장 많이 나타났다. PET/CT의 민감도, 특이도, 양성예측도, 음성예측도는 94.7%, 91.1%, 87.8%, 96.2%이고 혈청 CEA 치수는 44.7%, 97.3%, 91.8%, 72.3%였다. 종양표지 자와 PET/CT와의 비교에서는 PET/CT가 종양표지 자보다 민감도(94.2%, 52.1%)와 특이도(90.4%, 88.5%)가 높았다. 종양표지자와 CT를 종합하여 PET/CT와 비교하였을 때 민감도는 92.9%로 동일하였지만 특이도는 PET/CT가 91.3%로 높았다. 결론: 이러한 결과로 보아 FDG PET/CT가 근치적 절제술 후 대장암의 정기적 추적 관찰에도 유용하게 이용될 수 있을 것이다.

Purpose: Early detection of recurrence is an important factor for long term survival of patients with colorectal cancer. Measurement of serum levels of CEA, CA 19-9, CT and PET/CT has been commonly used in the postoperative surveillance of colorectal cancer. The purpose of this study was to compare the diagnostic ability of PET/CT, tumor marker and CT for recurrence in colorectal cancer patients after treatment. Materials and Methods: F-18 FDG PET/CT imaging was performed in 189 colorectal cancer patients who underwent curative surgical resection and/or chemotherapy. Measurement of serum levels of CEA, CA 19-9 and CT imaging were performed within 2 months of PET/CT examination. Final diagnosis of recurrence was made by biopsy, radiologic studies or clinical follow-up for 6 months after each study. Results: Overall sensitivity, specificity of PET/CT was 94.7%, 91.1%, while those of serum CEA were 44.7% and 97.3%, respectively. Sensitivity and specificity were 94.2%, 90.4% for PET/CT and better than those of combined CEA and CA 19-9 measurement(52.1%, 88.5%) in 174 patients measured available both CEA and CA 19-9 data. In 115 patients with both tumor markers and CT images available, PET/CT showed similar sensitivity but higher specificity(92.9%, 91.3%) compared to combination of tumor markers and CT images(92.9%, 74.1%). Conclusion: PET/CT was superior for detection of recurred colorectal cancer patients compared with both CEA, CA 19-9, and even with combination of both tumor markers and CT. Therefore PET/CT could be used as a routine surveillance examination to detect recurrence or metastasis of colorectal cancer.

키워드

참고문헌

  1. Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg 1995;130:1062-7 https://doi.org/10.1001/archsurg.1995.01430100040009
  2. Bellomi M, Rizzo S, Travaini LL, Bazzi L, Trifiro G, Zampino MG, et al. Role of multi detector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer. Radiol Med 2007;112:681-90 https://doi.org/10.1007/s11547-007-0172-2
  3. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Bur J Cancer 2007;43:1348-60
  4. Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancer-associated antigen in immumoperoxidase assay. Cancer Res 1982;42:4820-3
  5. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med 2001;28:1758-65 https://doi.org/10.1007/s002590100646
  6. Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH. Value of $^{18}$F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 2001;21:1375
  7. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759-67 https://doi.org/10.1007/BF02238010
  8. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, et al. Whole-body PET imaging with [$^{18}$F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-11 https://doi.org/10.1001/archsurg.134.5.503
  9. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20 https://doi.org/10.1007/BF02303744
  10. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK Jr. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201
  11. Zervos EE, Badgwell BD, Burak WE Jr, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with resumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 2001;130:636-43 https://doi.org/10.1067/msy.2001.116919
  12. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen(CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001;37:862-9 https://doi.org/10.1016/S0959-8049(01)00049-1
  13. Maldonado A, Sancho F, Cerdan J, Lozano A, Mohedano N, Jimenez J, et al. FDG-PET in the detection of recurrence in colorectal cancer based on using CEA level. Experience in 72 patients. Gin Positron Imaging 2000;3:170 https://doi.org/10.1016/S1095-0397(00)00082-0
  14. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319-23 https://doi.org/10.1097/00000658-199803000-00001
  15. Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ Jr, Pemberton JH, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27-32
  16. Cass AW, Million RR, Pfaff WW. Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer 1976;37:2861-65 https://doi.org/10.1002/1097-0142(197606)37:6<2861::AID-CNCR2820370643>3.0.CO;2-3
  17. Olson RM, Perencevich NP, Malcolm AW, Chaffey JT, Wilson RE. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer 1980;45:2969-74 https://doi.org/10.1002/1097-0142(19800615)45:12<2969::AID-CNCR2820451214>3.0.CO;2-7
  18. Turk PS, Wanebo HJ. Results of surgical treatment of nonhepatic recurrence of colorectal carcinoma. Cancer 1993;71(Suppl 12):4267-77 https://doi.org/10.1002/1097-0142(19930615)71:12+<4267::AID-CNCR2820711816>3.0.CO;2-O
  19. Kelly CJ, Daly JM Colorectal cancer. Principles of postoperative follow-up. Cancer 1992;70(Suppl 5):1397-408 https://doi.org/10.1002/1097-0142(19920901)70:3+<1397::AID-CNCR2820701531>3.0.CO;2-A
  20. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943-7 https://doi.org/10.1001/jama.270.8.943
  21. Wichmann MW, Miller C, Lau-Werner U, Strauss T, Lang RA, Homung HM, et al. The role of carcinoembryonic antigen for the detection of recurrent disease following curative resection of large-bowel cancer. Langenbeck's Arch Surg 2000;385:271-5 https://doi.org/10.1007/s004230000136
  22. Del Villano BC, Zurawski VR Jr. The carbohydrate antigenic determinant 19-9 (CA 19-9): a monoclonal antibody defined tumor marker. Lab Res Methods Biol Med 1983;8:269-82
  23. Kouri M, Pyrhonen S, Kuusela P. Elevated CA 19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992;49:78-85 https://doi.org/10.1002/jso.2930490204
  24. Kim SE, Shong YK, Cho BY, Kim NK, Koh CS, Lee M. Performance characteristic of CA 19-9 radioimmunoassay and clinical significance of serum CA 19-9 assay in patients with malignancy. Korean J Nucl Med 1985;19:119-26
  25. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czemin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-89
  26. Sarikaya I, Bloomston M, Povoski SP, Zhang J, Hall NC, Knopp MV, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 2007;5:64 https://doi.org/10.1186/1477-7819-5-64
  27. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer. comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22 https://doi.org/10.1016/S0748-7983(95)97046-0
  28. Arularnpalarn T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorecta1 cancer. Eur J Nucl Med 2001;28:1758-65 https://doi.org/10.1007/s002590100646
  29. Staib L, Schimneister H, Reske SN, Beger HG. Is $^{18}$F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000;180:1-5 https://doi.org/10.1016/S0002-9610(00)00406-2